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Differentiation
between reactive
gliosis and diffuse
astrocytoma by in situ
hybridization
Article abstract—The authors examined the use of chromosomal analysis
by in situ hybridization to differentiate between nonneoplastic reactive gliosis
and astrocytomas in cases in which routine histology was inconclusive. Nu-
merical chromosomal aberrations were found in 80% of low-grade astrocy-
toma specimens and in none of the reactive gliosis specimens. Aneusomic
tumor cells were detected in four of 13 stereotactic samples with an initially
inconclusive tissue diagnosis, three of which were later diagnosed as astrocy-
toma. The in situ hybridization procedure may have additional value in the
differential diagnosis of reactive gliosis versus low-grade astrocytoma.
NEUROLOGY 2001;56:1224–1227
P.H. Wessels, MD; A.H.N. Hopman, PhD; M.I.J. Ummelen; B. Krijne–Kubat, MD, PhD;
F.C.S. Ramaekers, PhD; A. Twijnstra, MD, PhD
Stereotactic biopsy specimens from patients with
low-grade diffuse astrocytomas may result in incon-
clusive diagnoses because of small sample size and
histopathologic heterogeneity.1 Attempts to differen-
tiate between a nonneoplastic and a neoplastic cause
of astrocytic proliferation have used a range of meth-
ods, such as the intra-operative cytologic wet smear
technique and additional immunohistochemical as-
says for p53 and Ki-67 antigen.
Conventional cytogenetic procedures can also be of
additional value in the differentiation between reac-
tive gliosis and astrocytoma. However, most of these
techniques only detect sporadic chromosomal aberra-
tions in low-grade astrocytoma, besides loss on chro-
mosome arm 17p and mutations of the p53 gene.2
The in situ hybridization (ISH) technique allows a
more frequent detection of chromosomal aberrations
in astrocytomas.3,4
The purpose of the current study was to determine
whether or not the ISH technique offers additional
diagnostic value by detecting tumor cells in areas of
low-grade astrocytomas that are not typical enough
to allow a morphologic diagnosis. The ISH results
were compared with the tumor cell proliferation (Ki-
67) index, which is considered to have additional
value in the differentiation between nonneoplastic
and neoplastic astrocytic proliferation.5
Materials and methods. Tissue material. The formalin-
fixed, paraffin-embedded archival material consisted of
three groups of tissue samples: reactive gliosis from pa-
tients who died from a nonneoplastic neurologic cause (n 5
10), low-grade diffuse astrocytomas (grade 2) (n 5 20), and
stereotactic biopsy specimens with an inconclusive tissue
diagnosis, i.e., no differentiation between nonneoplastic re-
active gliosis and low-grade astrocytoma (n 5 13).
Methods. In situ hybridization was performed follow-
ing a recently optimized protocol.6 The probes were specific
for the heterochromatin (sub)centromere region of chromo-
some 1 (1q12, pUC 1.77), the alphoid region of chromosome
7 (p7t1), and the centromere region of chromosome 10
(D10Z1). After overnight hybridization, the biotin labeled
DNA probes were indirectly detected by a peroxidase precip-
itation reaction. Diaminobenzidine was applied for visualiza-
tion of the peroxidase activity. Nuclear counterstaining was
done with hematoxylin or alternatively with 4,6-diamino-
phenylindol (DAPI). Monosomy was defined as .25% of nu-
clei with no or only one signal per nucleus. Nuclei were
classified trisomic if .5% of nuclei contained three or more
signals. Nuclei containing four or more signals were defined
as tetrasomic and polysomic.
The proliferation status was assessed as the Ki-67 im-
munostaining index, using the mouse monoclonal MIB-1
antibody (Immunotech S.A., Marseille, France) after anti-
gen retrieval by treatment with citrate buffer in a domestic
microwave oven for 10 minutes at 700 W.
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Results. Reactive gliosis. All evaluable cases (87%) of
reactive gliosis revealed disomy for all three chromosomes
(figure, A). Very sporadically, nuclei with three signals
were seen, but none of the samples met the criteria for
trisomy. In one sample with reactive gliosis the Ki-67 la-
beling index was 3.5%, whereas in the other samples it did
not exceed 1% (table 1).
Low-grade astrocytomas (grade 2). The mean age of
the patients with low-grade astrocytomas was 39.9 years
(range: 24 to 68 years) and the median interval to tumor
progression was 35 months. Numerical chromosomal aber-
rations for one or more of the chromosomes investigated
were present in 80% of the low-grade astrocytomas: in 60%
for chromosome 1, in 65% for chromosome 7, and in 50%
for chromosome 10 (see table 1). Only one sample showed
monosomy for chromosomes 1 and 7. All other aberrations
comprised trisomy, tetrasomy, and polysomy (see the fig-
ure, B). The mean Ki-67 labeling index in the astrocytomas
was 2.1% (range ,1 to 9%).
Cases with inconclusive diagnosis. All samples with
inconclusive tissue diagnosis were stereotactic biopsy spec-
imens in which it was not possible to distinguish between
reactive gliosis and diffuse astrocytoma on the basis of
routine histology. Revision of one sample, derived from a
patient with a suspected recurrent astrocytoma after ra-
diotherapy, revealed endothelial cell proliferation and ne-
crosis, which we considered to be nonneoplastic radiation
damage. In all other samples neuropathologic revision
agreed with the initial inconclusive diagnosis. On the basis
of follow-up data, the samples could be divided into three
groups, for which ISH results and Ki-67 labeling indices
are shown in table 2.
1. Samples in which astrocytoma was diagnosed at a
later stage (Cases 1 to 7): In three of these samples (Cases
1 to 3) the primary biopsy already showed numerical chro-
mosomal aberrations (figure, C). Ki-67 labeling indices of
these samples were 1, 10, and 5%. In Case 7 no confirma-
tion of malignancy was obtained but higher-grade astrocy-
toma was diagnosed by combining histopathology and
clinical and radiologic progression of the space-occupying
lesion.
2. Samples in which the follow-up period was too short
and in which a second biopsy or resection was deferred
(Cases 8 to 11): In Case 8, the primary biopsy showed
numerical chromosomal aberrations for chromosomes 1
and 7. The Ki-67 labeling index of this sample was less
than 1%.
3. Samples in which a nonneoplastic diagnosis was
made at a later stage (Cases 12 to 13): Case 12 showed no
numerical chromosomal aberrations, and Case 13 was not
evaluable by ISH due to cell lysis.
Discussion. The current study showed that in
some cases with inconclusive histologic diagnoses the
ISH technique allows differentiation between reac-
tive gliosis and diffuse astrocytoma. Because the dis-
tinction between these two histomorphologic entities
is often difficult, this finding has potential clinical
relevance.
None of the samples with reactive gliosis showed
chromosomal aberrations, whereas 80% of the sam-
ples containing evident low-grade astrocytomas were
classified as genetically aberrant for chromosomes 1,
Figure. Routine microscopy and in situ hybridization
(ISH) with a probe for chromosome 7 in samples from the
investigated groups. No numerical chromosomal aberra-
tions are present in the sample with nonneoplastic reactive
gliosis (A), whereas in both the low-grade astrocytoma (B)
and the sample with an inconclusive tissue diagnosis (C)
frequent nuclei with three (trisomy), four (tetrasomy), and
more than four signals (polysomy) are present. Microscopy
before reduction: 3 200; ISH: (A, B) 3 800, (C) 3 1,000.
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7, and/or 10. The absence of numerical chromosomal
aberrations in the nonneoplastic reactive gliosis cor-
roborates the findings of the only previous ISH study
in gliotic brain tissue.7
The ISH technique is more efficient in finding
chromosomal aberrations in astrocytomas than clas-
sic karyotyping or loss of heterozygosity studies be-
cause all interphase cells can be evaluated. Earlier
ISH studies on small series of low-grade astrocyto-
mas have already revealed hyperdiploid cells, gain of
chromosome 7, loss of chromosome 10, and aberra-
tions of chromosomes 1 and 17.3,4,8,9 Using three chro-
mosome probes with single-target ISH analysis
allowed us to detect high percentages of aneusomic
cells in most low-grade astrocytomas.
ISH detected aneusomies in four samples with an
initial inconclusive tissue diagnosis. Of these four
cases, three showed rapid progression to high-grade
astrocytoma. However, this may also suggest that
these patients, whose differential tissue diagnosis
was a choice between reactive gliosis and low-grade
astrocytomas, most probably had higher-grade astro-
cytomas, which were not detected at first diagnosis
because of sampling errors. In the fourth case, no
progression was seen after 4 months of follow-up.
Because of the high frequency of genetic aberrations
in this case, the patient is now being clinically mon-
itored on a regular basis.
Our findings indicate that the detectability of ge-
notypic alterations extends well beyond the histo-
morphologic border of astrocytomas.
Two of the four inconclusive cases had high Ki-67
labeling indices, which supports the highly malig-
nant character of these lesions. However, the two
other lesions had low Ki-67 levels, suggesting that
this marker has a lower sensitivity for the detection
of lesions with a malignant clinical course than the
ISH technique.
Table 1 Summarized results of numerical chromosomal aberrations and Ki-67 labeling index (LI) for the three investigated patient
groups
Diagnosis N
Number of samples with numerical
chromosomal aberrations (%)
Aberrant for one or
more chromosomes (%)
Ki-67 LI,
% cells (range)Chr. 1 Chr. 7 Chr. 10 Chr. 1, 7, and/or 10
Gliosis 10 0 0 0 0 ,1 (,1–3)
Astrocytoma 20 12 (60) 13 (65) 10 (50) 16 (80) 2.1 (,1–9)
Inconclusive 13 3 (23) 4 (31) 1 (8) 4 (31) 2 (,1–10)
Chr. 5 chromosome.
Table 2 In situ hybridization results and Ki-67 labeling index in samples with uncertain tissue diagnosis
Case No.
Numerical chromosome aberrations (%)
Ki-67 LI,
% cells Follow-up, mo.Chromosome 1 Chromosome 7 Chromosome 10
Malignant progression
1 Tri (10%) Tri (10%) Tri (5%) 5 Postmortem: GBM, l0
2 Tri (21%) Tri (19%), Tetra (11%), Poly (1%) D 1 Resection: AA, 5
3 D Tri (25%) D 10 Second biopsy: GBM, 2
4 D D D ,1 Resection: AA, 4
5 D D D ,1 Second biopsy: GBM, 1
6 D D NE ,1 Second biopsy: GBM, 40
7 D D D 4 MRI, 35
No progression in time followed
8 Tri (10%) Tri (32%), Tetra (9%) NE ,1 4
9 D D NE ,1 20
10 D D D ,1 6
11 D D D ,1 22
Nonmalignant diagnosis
12 D D D ,1 Multiple sclerosis
13 NE NE NE NE Radiation necrosis
D 5 disomy; Tri 5 trisomy; Tetra 5 tetrasomy; Poly 5 polysomy; NE 5 not evaluable; AA 5 anaplastic astrocytoma; GBM 5 glioblas-
toma; MRI 5 progression on MRI; Ki-67 L1 5 Ki-67 labeling index.
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Because the numbers in the investigated groups
were relatively small, the role that chromosomal ab-
normalities can play in the diagnosis of astrocytomas
needs confirmation in a larger series of cases.
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Guillain–Barré
syndrome associated
with IgG monospecific
to ganglioside GD1b
Article abstract—The authors examined serum antiglycolipid antibodies in
445 patients with Guillain–Barré syndrome (GBS). Among them, nine had
anti-GD1b IgG antibodies with no reactivity to other glycolipids tested. All
those patients had sensory disturbance, and none had the primary axonal
form. Anti-GD1b IgG antibodies may bind to primary sensory neurons and
paranodal myelin, where GD1b is localized, and be involved in the pathogen-
esis of sensory disturbance and demyelination. However, more study is
needed to substantiate the roles of anti-GD1b IgG antibodies.
NEUROLOGY 2001;56:1227–1229
T. Miyazaki, MD, PhD; S. Kusunoki, MD, PhD; K. Kaida, MD; M. Shiina, MD, PhD;
and I. Kanazawa, MD, PhD
Guillain–Barré syndrome (GBS) is an acute motor-
dominant inflammatory neuropathy. A significant
increase in the titers of various kinds of antiganglio-
side antibodies in the acute phase sera from patients
with this syndrome has been reported. The relation-
ship between presence of antiganglioside antibodies
and a certain clinical feature has been discussed.
Ganglioside GD1b is localized in dorsal root gan-
glia (DRG) neurons and in the paranodal myelin of
human peripheral nerve.1 Three patients with GBS,
exhibiting an increase in the level of the monospe-
cific anti-GD1b IgG antibody, have been reported to
show clinical characteristics of acute cerebellar or
sensory ataxia.2-4 One patient with postinfection sen-
sory neuropathy and IgG anti-GD1b antibody also
has been reported.5 However, no report on clinical
features of GBS based on a large population of GBS
patients with the monospecific anti-GD1b IgG anti-
body has been published.
Methods. Samples. Serum samples from patients ful-
filling the criteria for GBS proposed by Asbury and Corn-
blath6 were obtained from several hospitals throughout
Japan between December 1992 and June 1999. Serum
samples from cases showing progression of GBS beyond 4
weeks, marked laterality of limb muscle weakness, or high
CSF cellular count (more than 50) were excluded from the
study. Antibody immunoreactivities against gangliosides
(GM1, GM2, GM3, GD1a, GD1b, GalNAc-GD1a, GM1b,
GD3, GT1b, GQ1b), GA1, and galactocerebroside were as-
sayed in our laboratory.7
Patient group. We investigated clinical features such
as clinical course, symptoms, and electrophysiologic find-
ings of patients with GBS whose sera had anti-GD1b IgG
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